Last Update 03 May 26

CCRN: Higher Margin Segments And Travel Nurse Demand Will Support Future Margins

The analyst price target on Cross Country Healthcare has shifted modestly higher, with recent research pointing to a range between $10 and $14. Analysts highlight improving travel nurse demand, confidence in a 4% to 5% adjusted EBITDA margin target by the end of 2026, and opportunities in higher margin segments.

Analyst Commentary

Recent Street research on Cross Country Healthcare has centered on the reset price targets, the company’s margin ambitions through 2026, and the role of travel nurse demand in supporting growth in higher margin segments.

Bullish Takeaways

Bullish analysts see the move in price targets into the US$10 to US$14 range as better aligning the share price with Cross Country Healthcare's margin goals and segment mix, rather than a call based on short term trading momentum.
Confidence around the 4% to 5% adjusted EBITDA margin objective by the end of 2026 is tied to a tilt toward higher margin business lines and expectations for operating leverage as scale improves.
Improving travel nurse demand is viewed as an important volume support, which, combined with a focus on richer margin segments, is seen as helpful for earnings quality and consistency of execution.
Some bullish researchers frame 2025 as a distracting year, and argue that a clearer set of priorities around margins and growth segments could help reduce execution risk beyond that period.

Bearish Takeaways

Bearish analysts, or those keeping a neutral view, continue to see enough uncertainty around the timing and durability of travel nurse demand that they are hesitant to assign a more aggressive valuation multiple.
The 4% to 5% adjusted EBITDA margin target is treated as an aspiration rather than a base case by more cautious researchers, who point to the need for consistent execution on cost control and mix shift.
There is some concern that the improvement story relies heavily on successfully growing higher margin segments, which can be competitive and may require ongoing investment that could weigh on near term profitability.
Neutral stances also reflect the view that, even with raised targets, the current setup does not yet offer a clear enough risk or reward skew until investors see firmer evidence on margins and growth through 2026.

What's in the News

Cross Country Healthcare was removed from the S&P Health Care Services Select Industry Index, which may affect how some index and benchmark-driven investors view the stock (Index Constituent Drops).
From October 1, 2025 to December 31, 2025, the company repurchased 803,175 shares, representing 2.47%, for US$6.51 million, completing a total buyback of 6,433,235 shares, or 18.49%, for US$124.62 million under the program announced on August 16, 2022 (Buyback Tranche Update).
Management indicated on the Fourth Quarter 2025 earnings call that the company is actively looking for acquisitions, with a focus on complementary deals tied to its existing customer footprint, technology platform, home based staffing division, and locum tenens offerings, while also continuing share repurchases as part of a disciplined capital allocation approach (Seeking Acquisitions/Investments).
For the first quarter of 2026, Cross Country Healthcare issued revenue guidance in the range of US$235 million to US$240 million, providing a reference point for how management is framing near term activity levels (Corporate Guidance).

Valuation Changes

Fair Value: Modelled fair value remains unchanged at $11.67 per share.
Discount Rate: Discount rate is steady at 6.98%, indicating no change in the required return used in the valuation model.
Revenue Growth: Implied long term revenue growth input is effectively unchanged at 73.15%.
Net Profit Margin: Long term profit margin assumption is effectively flat at 100.22%.
Future P/E: Future P/E multiple is unchanged at 39.68x, reflecting consistent valuation assumptions for forward earnings.

1 view

Key Takeaways

Increased demand and strategic investments in Travel Nursing and Physician Staffing segments drive significant revenue and growth potential.
Expansion of home care and technology integrations enhances margins and client retention, supporting long-term financial stability and growth.
Cross Country Healthcare faces significant revenue and margin pressure due to competitive compensation, market bill rate discrepancies, and delayed new deal revenues, impacting future profitability.

Catalysts

About Cross Country Healthcare

Provides talent management and other consultative services for healthcare clients in the United States.What are the underlying business or industry changes driving this perspective?

Cross Country Healthcare has seen an approximately 20% increase in orders in the Travel Nursing & Allied segment for the fourth quarter, indicating a potential inflection point and future volume growth, which may positively impact revenue.
The home care staffing segment is projected to grow in the mid-teens year-over-year in the fourth quarter and continues to expand its PACE programs nationwide, boosting revenue growth and potentially improving net margins due to a higher margin profile.
The Physician Staffing segment is experiencing strong demand, with expected low to mid-single-digit sequential revenue growth in the fourth quarter, facilitated by improved operating leverage and cost management, which should enhance both revenue and contribution income.
The company’s technology platform, Intellify, is expected to fully integrate all clients by the end of the year, which is anticipated to increase spend under management and drive revenue growth through improved margin contracts and client retention.
Cross Country Healthcare is focusing on capital allocation for potential M&A opportunities and strategic investments in technology, which could further expand the portfolio and enhance earnings growth while maintaining a strong balance sheet with no outstanding debt.

Cross Country Healthcare Earnings and Revenue Growth

Cross Country Healthcare Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cross Country Healthcare's revenue will remain fairly flat over the next 3 years.
Analysts assume that profit margins will increase from -9.0% today to 1.0% in 3 years time.
Analysts expect earnings to reach $10.8 million (and earnings per share of $0.33) by about May 2029, up from -$94.9 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.0x on those 2029 earnings, up from -3.5x today. This future PE is greater than the current PE for the US Healthcare industry at 24.9x.
Analysts expect the number of shares outstanding to decline by 1.42% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Cross Country Healthcare faces gross margin pressures due to competitive compensation packages in the Travel Nursing and Allied markets, impacting its profitability and ability to normalize margins in the near term. This could affect net margins negatively.
The company's revenue in the third quarter of 2024 was down 7% sequentially and 29% year-over-year, primarily due to expected declines in Travel Nursing and Allied. This potential continuing decline poses a risk to overall revenue growth.
Over 50% of job orders are not at market bill rates, which could limit Cross Country Healthcare's ability to increase production and fill assignments, potentially impacting revenue growth and overall earnings.
Despite expectations of growth, the Physician Staffing segment might face capacity limits and increased costs if additional resources are needed to sustain growth, impacting net margins.
While the company is focusing on M&A opportunities, the longer decision-making cycles at hospitals for MSP and VMS contracts could delay potential revenue from new deals, affecting revenue projections and net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $11.67 for Cross Country Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $10.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.1 billion, earnings will come to $10.8 million, and it would be trading on a PE ratio of 41.0x, assuming you use a discount rate of 7.0%.
Given the current share price of $10.23, the analyst price target of $11.67 is 12.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cross Country Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Full Client Integration With Intellify Will Improve Client Retention